any thoughts on which trial will be more difficult to pass? also which one offers the best market opportunity?
from memory lucentis more effective drug
Ann: Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens, page-15
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
58.5¢ |
Change
0.030(5.41%) |
Mkt cap ! $720.1M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 58.5¢ | 54.0¢ | $1.386M | 2.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34043 | 58.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.5¢ | 33845 | 3 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |